3A-(4-Bromo-Phenyl)-Hexahydro-Pyrano[3,4-B]Pyrrole-1-Carboxylic Acid Tert-Butyl Ester

During the scale-up of a dual orexin receptor antagonist (DORA) aimed at insomnia, the coupling partner for the pyrido[3,4-b]pyrazine fragment was accessed via a protected hexahydro-pyrano[3,4-b]pyrrole scaffold bearing a 4-bromophenyl group at the 3a-position. The N-Boc carbamate remains intact through a Pd-mediated Suzuki–Miyaura cross-coupling that installs a 2-(1,2,3-triazol-4-yl)-pyridine residue, delivering the penultimate intermediate with an overall isolated yield of 78% after column chromatography and trituration in n-heptane/EtOAc (10:1). On a 200-L Hastelloy reactor equipped with a retreat-blade impeller, the heterogeneous mixture of K₃PO₄ (1.5 M aqueous), the bromo building block (1.0 eq.), and the triazolyl-pyridine boronate ester (1.15 eq.) was deoxygenated via three N₂-vacuum purge cycles before Pd(OAc)₂ (0.8 mol%) and XPhos (2.0 mol%) were injected as a preformed catalyst solution in degassed THF. The internal temperature was maintained at 58 ± 3°C for 6 h; excursions beyond 62°C triggered a sharp increase in the protodebrominated impurity from 2.1% to 11% area by HPLC, attributed to a β-hydride elimination pathway competing with transmetallation when the phosphine ligand dissociates. The crude, after filtration through a Celite® pad and phase split with brine, was concentrated under vacuum (≤ 45°C jacket) to avoid premature Boc cleavage, which was observed at residual water content above 0.15% once the temperature exceeded 50°C. Subsequent Boc removal proceeded in a 100-L glass-lined vessel with anhydrous HCl (1.4 M in 1,4-dioxane, 5.0 eq.) at 20–25°C under nitrogen, achieving full conversion within 90 min; excess HCl was stripped with three toluene chases to ≤ 50 ppm Cl^– before the free base was liberated with aqueous Na₂CO₃ and extracted into MTBE. The resulting secondary amine was telescoped into amide coupling with 5-chloro-2-((2R)-1-methylpyrrolidin-2-yl)-pyridine using HATU (1.2 eq.) and DIPEA (3.0 eq.) in DMF at 0–5°C, affording the final DORA candidate after recrystallization from iPA/water. Key quality criteria for the BOC-protected intermediate include HPLC (Inertsil ODS-3V, 250 × 4.6 mm, gradient 30–95% MeCN in 0.1% TFA, 1.0 mL/min) purity ≥ 99.0%, residual palladium ≤ 10 ppm (ICH Q3D Option 2A), and benzyl bromide analog content ≤ 0.10% by UPLC–MS. During 12 commercial batches, the largest source of batch-to-batch variance was the moisture content of the XPhos catalyst stock, which, if not dried over activated 4 Å molecular sieves for 24 h, led to 3–5% lower conversion and necessitated a re-work with an additional 0.2 mol% of catalyst.

Kinase Inhibitor Fragment Elaboration: Exploiting the Bromine Handle

The 4-bromophenyl substituent of 3a-(4-bromo-phenyl)-hexahydro-pyrano[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester functions as a universal vector for C–C bond formation in the assembly of type II and type II½ kinase inhibitors. In a representative discovery campaign targeting Tie-2 and VEGFR-2, the bromide was converted into a boronate via a Miyaura borylation using bis(pinacolato)diboron (1.5 eq.), PdCl₂(dppf)·CH₂Cl₂ (3.0 mol%), and AcOK (3.0 eq.) in 1,4-dioxane at 95°C, yielding the pinacol ester in 92% after purification by flash chromatography. The subsequent one-pot Suzuki coupling with a 3-iodo-1H-indazole-5-carboxylic acid methyl ester (synthesized via Sandmeyer reaction) was executed under the same catalyst system by adding the iodopyrazole after 4 h and heating for an additional 10 h; the sequence eliminated the need to isolate the moisture-sensitive boronate and reduced the total step count. On a 50-L scale, however, the borylation step exhibited a 7-minute induction period that was traced to residual oxygen in the bis(pinacolato)diboron lot — the problem was resolved by pre-stirring the dioxane solution with 0.5 wt% NaBH₄ for 30 min prior to charging the palladium precatalyst. The elaborated biaryl intermediate, retaining the Boc-carbamate, was then deprotected using TFA/CH₂Cl₂ (1:4 v/v, 10 vol) in the presence of triisopropylsilane (2% v/v) as a cation scavenger; without the silane, dimeric N-alkylated byproducts reaching 4.7% area were detected by LCMS. The free amine was engaged in a reductive amination with 4-formyl-N-[4-(piperidin-4-ylcarbamoyl)-phenyl]-benzamide in the presence of NaBH(OAc)₃ (1.8 eq.) and HOAc (0.5 eq.) in 1,2-dichloroethane at room temperature, giving the final kinase inhibitor precursor in 81% isolated yield after salt exchange with methanesulfonic acid. Residual boron levels in the API precursor were monitored by ICP-OES and consistently remained below 50 ppm, well within the 2400 μg/day permitted daily exposure for the methanesulfonate salt. Notably, the hexahydro-pyrano[3,4-b]pyrrole ring itself can participate in hydrogen-bonding contacts with the kinase hinge region; single-crystal X-ray data of a co-crystal with CDK2 showed that the pyran oxygen accepts a hydrogen bond from Leu83 backbone NH (distance 2.9 Å), rationalizing the selectivity shift over the morpholine analog.

What Limits the Use of Tert-Butyl Ester Protecting Groups in mGlu₂ PAM Manufacturing?

Positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor frequently incorporate a 3a-aryl-hexahydro-pyrano[3,4-b]pyrrole core to fill the lipophilic back pocket adjacent to the allosteric site. In the convergent route to a pyrazolo[3,4-d]pyrimidinone-containing mGlu₂ PAM that entered IND-enabling toxicology, the tert-butyl ester of the title building block was used to mask the pyrrolidine nitrogen during the Mitsunobu coupling with a phenol. Under typical conditions with DIAD (1.3 eq.) and PPh₃ (1.3 eq.) in THF at 0°C to rt, 42% of the Boc group was prematurely cleaved, forming the corresponding secondary amine that subsequently participated in a N-alkylation side reaction, reducing the yield of the desired ether to 37%. The problem was attributed to the in situ generation of traces of hydrazoic acid from DIAD decomposition, which is known to protonate Boc-carbamates. Switching to ADDP (1,1’-(azodicarbonyl)dipiperidine) and n-Bu₃P in toluene at −10°C eliminated the protolytic deprotection, and the ether was obtained in 89% with ≤ 0.3% des-Boc impurity. The tolerance of the Boc group to the subsequent Ullmann-type etherification step was assessed by DSC: the onset temperature for autocatalytic decomposition of the neat intermediate was 123°C (heating rate 5 K/min), mandating that the coupling be conducted at ≤ 80°C with a CuI load of 5 mol% and N,N,N’-trimethylethylenediamine (10 mol%) in DMF. After aqueous workup, the crude was crystallized from MTBE/n-heptane (1:2) to furnish the intermediate in a form consistently passing the polymorphic stability test (XRPD pattern unchanged after 14 days at 40°C/75% RH). The final deblock was carried out with 4 M HCl in CPME at 35°C for 2 h, delivering the hydrochloride salt directly, which was then acylated with the pyrazolo-pyrimidinone acid chloride prepared from the corresponding carboxylic acid using (COCl)₂/DMF catalytic. Purity of the final PAM, analyzed by a chiral HPLC method (Chiralpak IG, 250 × 4.6 mm, n-hexane/EtOH/DEA 70:30:0.1), was 99.4% (ee 99.8%). The bromine atom had been removed three steps earlier via catalytic hydrogenolysis over 5% Pd/C in EtOAc/EtOH at 40 psi H₂, a transformation that proceeded without pyran ring reduction when the catalyst was pre-poisoned with 0.1 eq. of 2,6-lutidine. An important limitation: the pyrano ring undergoes slow hydrolysis in acidic aqueous media (t_1/2 ~8 h at pH 2.0, 25°C), so all acidic workups must be quenched within 60 min to keep the ring-opened diol impurity below 0.15%.

The tert-butyl carbamate of the 3a-(4-bromophenyl) derivative has been qualified as an analytical marker for process-related impurities according to ICH Q3A and Q3B guidelines in the submission of a DORA candidate. A batch of the building block with a purity of 99.82% (HPLC at 254 nm) was subjected to forced degradation conditions: 1 M HCl, 60°C, 4 h (acid hydrolysis); 0.1 M NaOH, 40°C, 2 h (base); 3% H₂O₂, rt, 24 h (oxidative); and UV light (254 nm, 200 W·h/m²). Four degradation products were identified: des-Boc amine, the debrominated des-Boc, the ring-expanded analogue resulting from oxygen insertion, and a dimeric N,N’-methylene-linked species derived from formaldehyde generated by Boc decomposition. Separation of all five components was achieved on a Waters Cortecs C18+ column (150 × 3.0 mm, 2.7 μm) with a gradient of ammonium acetate buffer (pH 5.8) and acetonitrile, allowing the marker to be used as a system suitability standard. The relative response factor of the des-Boc amine was determined to be 1.12 against the Boc compound at 254 nm. For routine batch release, the acceptance criterion was set as total impurities ≤ 0.5% and no single unknown impurity ≥ 0.10%, in line with Ph. Eur. monograph 2034. The material is stored in amber HDPE drums with desiccant pouches; if exposed to relative humidity above 60% for more than 48 h, an increase in the des-Boc impurity from 0.05% to 0.22% has been documented, prompting a mandatory re-test every 12 months under ICH stability storage conditions.

Managing Palladium Carryover in Late-Stage Functionalization

A dedicated sequence employing the bromo building block as a substrate for a Buchwald–Hartwig amination was developed to install a 4-(piperazin-1-yl)benzonitrile moiety, delivering a GPR119 agonist preclinical candidate. The systematic optimization of the coupling, conducted on a 5-g scale in a parallel reactor, is summarized in the table below because exceeding 0.8 mol% Pd₂(dba)₃ led to an unacceptable palladium bleed into the isolated solid that could not be reduced to ≤ 10 ppm by standard activated charcoal treatment or TMT (trimercaptotriazine) scavenger resin.

The RuPhos-based system afforded 99% conversion and, after an aqueous diethyldithiocarbamate wash (pH 5.5) and crystallization from iPA/water, reduced palladium to 6 ppm. Notably, the use of Cs₂CO₃ was mandatory because K₂CO₃ or NaOtBu promoted 12–18% base-mediated aryl ether formation involving the pyran oxygen. The resulting N-arylated intermediate underwent Boc deprotection with HCl in iPA, followed by amidation with 4-(methylsulfonamido)butanoic acid using EDC·HCl/HOBt in DMF, affording the GPR119 agonist hydrochloride with an overall yield of 64% over four steps. Quality ICH Q3D compliance required the palladium content to be ≤ 10 ppm; the Ecosorb C-941 treatment met this specification in 9 out of 10 validation runs.

Can the Hexahydro-pyrano[3,4-b]pyrrole Core Replace the Morpholine Substructure in 5-HT_2C Agonists?

Replacement of the morpholine appendage with a conformationally restricted hexahydro-pyrano[3,4-b]pyrrole in a series of aryl sulfonamide-derived 5-HT_2C agonists was explored to reduce CYP2D6 inhibitory activity. The title compound was elaborated by first hydrolyzing the tert-butyl ester under lithium hydroxide in a THF/MeOH/water (2:2:1) mixture to give the corresponding carboxylic acid, which was then coupled with 2,5-difluoroaniline using HATU/DIPEA. The resulting amide retained the 4-bromophenyl group, which was subsequently replaced with a 2,4-difluoro-phenyl group via Suzuki coupling with 2,4-difluorophenylboronic acid catalyzed by Pd(PPh₃)₄ (2 mol%) and Na₂CO₃ in dioxane/water at 85°C. The Boc group was removed last with TFA/CH₂Cl₂ (1:1), and the pyrrolidine nitrogen was sulfonylated with 2-(trifluoromethoxy)benzenesulfonyl chloride in pyridine at 5°C. A key regulatory observation: the sulfonamide-forming step generated a mutagenic impurity alert from residual benzenesulfonyl chloride, requiring a dedicated clearance study per ICH M7. Control was established by limiting the benzenesulfonyl chloride charge to 1.02 eq. and adding a post-reaction iPA quench at 40°C for 1 h, which reduced the sulfonate ester byproduct to ≤ 2 ppm. The final agonist exhibited an EC₅₀ of 8.3 nM at 5-HT_2C in a FLIPR assay while the CYP2D6 IC₅₀ shifted from 0.9 µM (morpholine analog) to 14 µM, validating the scaffold swap. Crystallinity was poor, and the free base was converted to a mesylate salt in acetone, which exhibited a melting onset of 211.3°C (DSC) and an aqueous solubility of 2.1 mg/mL at pH 6.8, enabling oral formulation development.